Less Effect of Intranasal Than Oral Hormone Therapy on Factors Associated With Venous Thrombosis Risk in Healthy Postmenopausal Women

@article{Hemelaar2006LessEO,
  title={Less Effect of Intranasal Than Oral Hormone Therapy on Factors Associated With Venous Thrombosis Risk in Healthy Postmenopausal Women},
  author={M. Hemelaar and J. Rosing and P. Kenemans and M. Thomassen and D. Braat and M. J. van der Mooren},
  journal={Arteriosclerosis, Thrombosis, and Vascular Biology},
  year={2006},
  volume={26},
  pages={1660-1666}
}
Objective—To compare the effects of intranasal and oral administration of 17&bgr;-estradiol (E2) and norethisterone(acetate) [NET(A)] in healthy postmenopausal women on activated protein C (APC) resistance and other hemostatic parameters associated with venous thrombosis. Methods and Results—In this 2-center, randomized, double-blind, 1-year trial, 90 postmenopausal women (56.6±4.7 years of age) received daily either an intranasal spray with 175 &mgr;g/275 &mgr;g E2/NET (n=47) or 1 mg/0.5 mg… Expand
Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy: a randomized trial
TLDR
During intranasal E2/NET therapy, changes in the coagulatory and fibrinolytic markers were to some extent less than those observed during oral therapy. Expand
Effects of intranasal versus oral hormone therapy on asymmetric dimethylarginine in healthy postmenopausal women: a randomized study.
TLDR
The decrease in ADMA by oral estrogens could be a key phenomenon in the modulation of nitric oxide synthesis by postmenopausal hormone therapy. Expand
Effects of nonoral estradiol-micronized progesterone or low-dose oral estradiol-drospirenone therapy on metabolic variables and markers of endothelial function in early postmenopause.
TLDR
Neither treatment induced deleterious effects in the short term on variables related to cardiovascular risk in early postmenopausal women. Expand
Effects of ultra-low-dose versus standard hormone therapy on fibrinolysis and thrombin generation in postmenopausal women.
TLDR
In contrast to the standard HT, ultra-low-dose HT may enhance fibrinolysis through reduced PAI-1 levels, and led to higher F1+2 and FVIII activity. Expand
Plasma fibrin clot properties in postmenopausal women: effects of hormone therapy
TLDR
Estrogen plus progestogen therapy has a minor effect on plasma fibrin properties, but leads to the formation of thicker and more branched fibr in fibers, particularly during oral administration. Expand
Effect of estrogen-progestin hormonal replacement therapy on blood coagulation and fibrinolysis in postmenopausal women.
TLDR
The CEE associated with MP treatment may reduce AT levels, whereas unopposed CEE or transdermal 17beta-estradiol plus MP does not change AT, and hormonal replacement therapy may increase the risk of thrombosis in women with congenital or acquired thromBophilia. Expand
Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: a systematic review.
TLDR
Compared with oral HT, non-oral HT appears be safer with respect to atherosclerotic and venous thromboembolic disease risk, and has minor effects on the other cardiovascular risk markers studied. Expand
Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen
TLDR
Transdermal estrogens combined with norpregnanes may induce APC resistance and activate blood coagulation and provide a biological support to epidemiological data regarding the potential thrombogenic effects of norPregnanes. Expand
Prevention and treatment of venous thromboembolism during HRT: current perspectives
  • H. Rott
  • Medicine
  • International journal of general medicine
  • 2014
TLDR
Bioidentical hormone therapy via the transdermal route seems to be the safest opportunity for hormone replacement therapy, although large trials for bioidentical hormones therapy are needed. Expand
Effect of two oral doses of 17β‐estradiol associated with dydrogesterone on thrombin generation in healthy menopausal women: a randomized double‐blind placebo‐controlled study
TLDR
The aim of the study was to compare the effect of the standard dose of 17β‐estradiol to a lower one on thrombin generation (TG). Expand
...
1
2
...

References

SHOWING 1-10 OF 39 REFERENCES
Effect of Oral and Transdermal Estrogen Replacement Therapy on Hemostatic Variables Associated With Venous Thrombosis: A Randomized, Placebo-Controlled Study in Postmenopausal Women
TLDR
The increase in resistance to APC was not explained by changes in protein S, protein C, or prothrombin and may contribute to the increased incidence of venous thrombosis in users of hormone replacement therapy. Expand
Differential Effects of Oral and Transdermal Estrogen/Progesterone Regimens on Sensitivity to Activated Protein C Among Postmenopausal Women: A Randomized Trial
TLDR
The data show that oral, unlike transdermal, estrogen induces APC resistance and activates blood coagulation, and emphasize the importance of the route of estrogen administration. Expand
Effects of low-dose oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: a randomized placebo-controlled study.
TLDR
Low-dose oral estradiol therapy was associated with an increase in fibrinolysis and small decreases in procoagulant variables and transdermal therapy had minor effects. Expand
Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial.
TLDR
Oral estrogen/progesterone replacement therapy may result in coagulation activation and increased fibrinolytic potential, whereas opposed transdermal estrogen appears without any substantial effects on hemostasis. Expand
Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double‐blind, placebo‐controlled trial
TLDR
It is concluded that HRT diminishes the efficacy by which APC downregulates in‐vitro thrombin formation in a similar fashion to that observed with low‐dose oral contraceptives, but the increase in nAPCsr alone is not sufficient to explain the increased risk of VTE associated with use of HRT. Expand
Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk
TLDR
Oral but not transdermal ERT is associated with risk of VTE in postmenopausal women, and data suggest that transder mal ERT might be safer than oral ERT with respect to thrombotic risk. Expand
Clinical equivalence of intranasal and oral 17beta-estradiol for postmenopausal symptoms.
TLDR
Intranasal administration of 300 microg/d estradiol was at least as effective as oral administration of 2 mg/dEstradiol in alleviating postmenopausal symptoms, with less frequent mastalgia and uterine bleeding and without the metabolic consequences of the first-pass effect. Expand
Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: a 1-year, double-blind, placebo-controlled study. The Writing Group for the Estradiol Clotting Factors Study.
  • Medicine
  • Thrombosis and haemostasis
  • 1996
TLDR
Both regimens produce a clinically relevant decrease of fibrinogen levels; the continuous regimen affects also the levels of FVII and inhibitors suggesting that the haemostatic balance is shifted to a more physiological state. Expand
The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism--results from a randomized, double-blind, clinical trial.
TLDR
It is concluded that HRT was associated with early activation of coagulation, which corroborates the finding of an early risk of recurrent VTE and may be explained by reduction in circulating anticoagulants. Expand
Hormone replacement therapy with estradiol and risk of venous thromboembolism--a population-based case-control study.
TLDR
It is concluded that use of HRT containing estradiol was associated with a threefold increased risk of VTE, but this increased risk was restricted to the first year of use. Expand
...
1
2
3
4
...